Fig. 5
From: MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
MK-2206 prevents cisplatin- and olaparib-induced AKT phosphorylation. a PEO1 and PEO4 cells were treated with 1 μM MK-2206 in combination with 0.625 μM, 1.25 μM, or 2.5 μM cisplatin for 24 h. Levels of phosphorylated and total AKT and S6, and HSC-70 proteins were assessed by western blot analysis. b PEO1 and PEO4 cells were treated with 1 μM MK-2206 in combination with 0.625 μM, 1.25 μM, or 2.5 μM olaparib for 24 h. Levels of phosphorylated and total AKT and S6, and HSC-70 proteins were assessed by western blot analysis